Sign In
Buy NLSP
$0.762
+0 (+0%)
At Close: Mar 11, 2026
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
08:25am, Monday, 03'rd Nov 2025
ZURICH , Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for
NLS Pharmaceutics Ltd. and Kadimastem Ltd.
04:15pm, Thursday, 30'th Oct 2025
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
07:00am, Thursday, 30'th Oct 2025
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceu
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
07:00am, Wednesday, 29'th Oct 2025
ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
06:00am, Wednesday, 29'th Oct 2025
ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d
ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd.
The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel , Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (N
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
06:01am, Thursday, 23'rd Oct 2025
ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous sys
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
07:00am, Tuesday, 30'th Sep 2025
Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH , Sept.
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
06:00am, Wednesday, 10'th Sep 2025
ZURICH and NESS ZIONA, Israel , Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.
Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH , July 17, 2
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
07:00am, Monday, 30'th Jun 2025
Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss cli
NLS Pharmaceutics CEO Issues Letter to Shareholders
07:00am, Monday, 16'th Jun 2025
ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous syst
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
07:30am, Wednesday, 21'st May 2025
ZURICH , May 21, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, announces that it w
